Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Humana’s PDP membership shrinking

Executive Summary

Humana projects it will lose 1.1 million to 1.2 million members from its stand-alone Medicare prescription drug plans in 2009, due mainly to sharply higher premiums. The estimate includes auto-assigned members who were reassigned to plans with premiums below the low-income benchmark and low-income members who had voluntarily chosen Humana's plans, but who have now left to find less expensive coverage. Humana has backed away from coverage for low-income seniors because that business is too much of a drain on profits (1"The Pink Sheet," Sept. 15, 2008, p. 26). The firm's stand-alone PDP membership now totals about 2.1 million

You may also be interested in...



Humana Bows Out Of Medicare Part D Coverage For Dual Eligibles

In 2009, Humana will complete its exit from providing Medicare Part D benefits to low-income seniors who qualify for both Medicaid and Medicare coverage

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050689

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel